Cardiogenin Isomer Separation via Chiral Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for isolating cardiogenin from Geum japonicum fail to achieve high purity, with conventional techniques yielding a mixture of two closely eluting isomers, leading to uncertainty about impurities and their impact on biological activity.
Innovation Solution
A refined extraction and chromatographic process involving methanol re-slurry, filtration, dichloromethane extraction, n-butanol phase separation, Diaion HP-20 adsorption chromatography, silica gel chromatography, and high-pressure reverse-phase chromatography, followed by chiral phase or supercritical fluid chromatography, to isolate the major cardiogenin isomer with at least 98% HPLC purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional extraction and purification methods are used, then cardiogenin can be obtained, but the purity is insufficient and contains two closely eluting isomers
Solution Approach 1:
The patent applies segmentation by dividing the purification process into multiple distinct chromatographic steps: first chromatography to remove impurities, second chromatography to separate isomers, and optional third chromatography for further purification. Each step targets specific contaminants or isomers, progressively increasing purity from the initial mixture containing two closely eluting isomers to the final purified product with greater than 95% purity.
Solution Approach 2:
The patent employs local quality by using different stationary phases and mobile phase conditions for different chromatographic steps. The first chromatography uses one type of stationary phase while the second uses a different stationary phase optimized for separating closely eluting isomers. This localized optimization of separation conditions at each stage enables effective purification without requiring a single overly complex system.
2Manufacturing precision
If multiple chromatographic steps are implemented to increase purity, then isomer separation is achieved, but the process complexity and time increase
Solution Approach 1:
The patent applies preliminary action by performing the first chromatography step to remove bulk impurities before attempting to separate the closely eluting isomers in the second chromatography step. This preliminary removal of non-isomer impurities simplifies the subsequent isomer separation, making it more efficient and reducing the overall time required compared to attempting to separate isomers from a highly complex mixture in a single step.
Solution Approach 2:
The patent employs dynamics by using gradient elution in the chromatographic steps, where the mobile phase composition changes dynamically during the separation process. This allows for optimal separation of compounds with different polarities and affinities, enabling efficient isomer separation in a single run rather than requiring multiple static separations, thus reducing total processing time.
3Productivity
If high-pressure reverse-phase chromatography is used, then separation efficiency improves, but equipment requirements and operational complexity increase
Solution Approach 1:
The patent applies the intermediary principle by using a series of chromatographic columns with different stationary phases as intermediate separation stages. Rather than relying on a single high-pressure system to perform all separations, the process uses multiple lower-pressure chromatography steps with different selectivities, where each column acts as an intermediary that removes specific types of impurities or separates specific isomers, ultimately achieving high purification without requiring a single complex high-pressure system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process effectively separates the active major cardiogenin isomer from the inactive minor isomer, achieving substantial purity and stability, with the major isomer demonstrating enhanced cardiogenic differentiation capabilities in stem cells.
Implementation Method 1
subjecting the extract to chiral phase chromatography or supercritical fluid chromatography, whereby the major isomer is obtainable in isolated form
Implementation Method 2
subjecting the extract to chiral phase chromatography or supercritical fluid chromatography, whereby the major isomer is obtainable in isolated form
Implementation Method 3
Substantial purity would be achieved by crystallizing the isolated cardiogenin major isomer to separate the impurities
Implementation Method 4
The inventive methodology for isolating the cardiogenin major isomer also may comprise crystallizing the composition
Data Source
Figure 1
Figure 2~2B
Figure 3
AI summary
A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).